Tor-centric concept of regulation mitogenic, metabolic and energetic signal processing in cell

Tsitologiya

Volumn 54, Issue 8, 2012, Pages 589-602

  Zubova, S G ^a,b   Shitikova, Zh V ^a,b   Pospelova, T V ^a,b  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

^b ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

Author keywords

MTOR; Rapamycin; Senescence; Tumour growth

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN P53; TARGET OF RAPAMYCIN KINASE; TP53 PROTEIN, HUMAN;

ANIMAL; CELL PROLIFERATION; CELL TRANSFORMATION; GENETICS; HUMAN; LONGEVITY; METABOLISM; MOUSE; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LONGEVITY; MAP KINASE KINASE 4; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868655826     PISSN: 00413771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. Amano T., Tanabe K., Eto T., Narumiya S., Mizuno K. 2001. LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505. Biochem. J. 354:149-159.
2. Anisimov V. N., Zabezhinski M. A., Popovich I. G., Piskunova T. S., Semenchenko A. V., Tyndyk M. L., Yorova M. N., Antoch M. P., Blagosklonny M. V. 2010. Rapamycin extends maximal lifespan in cancer-prone mice. Amer. J. Pathol. 176:2092-2097.
3. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M. C., Rafii S., Pandolfi P. P. 2006. PML inhibits HIF-1 alpha translation and neoangiogenesis through repression of mTOR. Nature. 442:779-785.
4. Bierer B. E., Jin Y. J., Fruman D. A., Calvo V., BurakoffS. J. 1991. FK 506 and rapamycin: molecular probes of T-lymphocyte activation. Transplant Proc. 6:2850-2855.
5. Blagosklonny M. V. 2006. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle. 18:2087-2102.
6. Blagosklonny M. V. 2011. Progeria, rapamycin and normal aging: recent breakthrouth. Aging. 3:685-691.
7. Brunei A., Bonni A., Zigmond M. J., Lin M. Z., Juo P., Hu L. S., Anderson M. J., Arden K. C., Blenis J., Greenberg M. E. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96(6):857-868.
8. Bursch W., Ellinger A., Gerner C., Schulte-Hermann R. 2004. Autophagocytosis and programmed cell death. In: Autophagy. Georgetown: Landes Bioscience. IX. 287-303.
9. Cao K., Graziotto J. J., Blair C. D., MazulliJ. R., Erdos M. R., Krainc D., Collins F. S. 2011. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Science Transl. Med. 3:1-11.
10. Carling D. 2004. The AMP-activated protein kinase cascade - unifying system for energy control. Trends Biochem. Sci. 29:18-24.
11. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A. T., Thomas G., Kozma S. C., Papa A., Nardella C., Cantley L. C., Baselga J., Pandolfi P. P. 2008. Inhibition of mTORCl leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118:3065-3074.
12. Chua B. T., Volbracht C., Tan K. O., Li R., Yu V. C., Li P. 2003. Mitochondrial translocation of cofilin is an early step in apoptosis induction. Nat. Cell Biol. 12:1083-1089.
13. Coleman M. L., Densham R. M., Croft D. R., Olson M. F. 2006. Stability of p21Wafl/Cipl CDK inhibitor protein is responsive to RhoA-mediated regulation of the actin cytoskeleton. Oncogene. 25:2708-2716.
14. Corradetti M. N., Guan K.-L. 2006. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene. 25:6347-6360.
15. Curtis C., Landis G. N., Folk D., Wehr N. B., Hoe N., Waskar M., Abdueva D., Skvortsov D., Ford D., Luu A., Badrinath A., Levine R. L., Bradley T. J., Tavare S., Tower J. 2007. Transcriptional profiling of MnSOD-mediated lifespan extension in Drosophila reveals a species-general network of aging and metabolic genes. Genome Biol. 8:R262.
16. Datta S. R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M. E. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231-241.
17. De Duve C. 1963. The lysosome. Sci. Amer. 208:64-72.
18. Demidenko Z. N., Zubova S. G., Bukreeva E. I., Pospelov V. A., Pospelova T. V., Blagosklonny M. V. 2009. Rapamycin decelerates cellular senescence. Cell Cycle. 8:1888-1895.
19. Ding M., Li J., Leonard S. S., Shi X., Costa M., Castranova V., Vallyathan V., Huang C. 2002. Differential role of hydrogen peroxide in UV-induced signal transduction. Mol. Cell. Biochem. 234-235:81-90.
20. Dorman J. B., Albinder B., Shroyer T., Kenyon C. 1995. The age-1 and daf-2 genes function in a common pathway to control the lifespan of Caenorhabditis elegans. Genetics. 141:1399-1406.
21. Efstratiadis A. 1998. Genetics of mouse growth. Int. J. Develop. Biol. 42:955-976.
22. Eng C. P., Sehgal S. N., Vézina C. 1984. Activity of rapamycin (AY-22, 989) against transplanted rumors. J. Antibiot. (Tokyo). 37:1231-1237.
23. Feng Z., Zhang H., Levine A. J., Jin S. 2005. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Nat. Acad. Sci. USA. 102:8204-8209.
24. Floyd S., Favre C., Lasorsa F. M., Leahy M., Trigiante G., Stroebel P., Marx A., Loughran G., O'Callaghan K., Marobbio C. M., Slotboom D. J., Kunji E. R., Palmieri F., O'Connor R. 2007. The insulin-like growth factor-I-mTOR signaling pathway induces the mitochondrial pyrimidine nucleotide carrier to promote cell growth. Mol. Biol. Cell. 18:3545-3555.
25. Foster K. G., Fingar D. C. 2010. Mammalian target of rapamycin (mTOR) conducting the cellular signaling symphony. J. Biol. Chem. 285:14071-14077.
26. Fox H. L., Kimball S. R., Jefferson L. S., Lynch C. J. 1998. Amino acids stimulate phosphorylation of p70 (S6k) and organization of rat adipocytes into multicellular clusters. Amer. J. Physiol. Cell Physiol. 274:C206-C213.
27. Gourlay C. W., Ayscough K. R. 2005. The actin cytoskeleton: a key regulator of apoptosis and ageing? Nat. Rev. Mol. Cell Biol. 6:583-589.
28. Graff J. R., Konicek B. W., Vincent T. M., Lynch R. L., Monteith D., Weir S. N., Schwier P. 2007. Therapeutic suppression of translation initiation factor elF-4E expression reduced tumor growth without toxicity. J. Clin. Invest. 117:2638-2648.
29. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C. J., Zuelke C., Farkas S., Anthuber M., Jauch K. W., Geissler E. K. 2002. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8:128-135.
30. Guertin D. A., Sabatini D. M. 2007. Defining the role of mTOR in cancer. Cancer Cell. 12:9-22.
31. Guertin D. A., Stevens D. M., Thoreen C. C., Burds A. A., Kalaany N. Y., Moffat J., Brown M., Fitzgerald K. J., Sabatini D. M. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FO-XO and PKCalpha, but not S6K1. Develop. Cell. 11:859-871.
32. Harrington L. S., Findlay G. M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N. R., Cheng S., Shepherd P. R., Gout I., Downes C. P., Lamb R. F. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-223.
33. Harrison D. E., Strong R., Sharp Z. D., Nelson J. F., Astle C. M., Flurkey K., Nadon N. L., Wilkinson J. E., Frenkel K., Carter C. S., Pahor M., Javors M. A., Fernandez E., Miller R. A. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 460:392-395.
34. Harvey K. F., Mattilia J., Sofer A., Bennet F. C., Ramsey M. R., Ellisen L. W., Puig O., Hariharan I. K. 2008. FOXO-regulated transcription restricts overgrowth of Tsc mutant organs. J. Cell Biol. 180:691-696.
35. Heitman J., Mowa N. R., Hall M. N. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 253:905-909.
36. Heward C., Su Y., Cortez C., Tan R., Harman S. M. 2007. A multi-parameter biomarker set for oxidativ stress assessment in human samples. Current directions in studying mechanisms of aging. Age. 29:109.
37. Holzenberger M., Dupont J., Ducos B., Leneuve P., Géloën A., Even P. C., Cervera P., Le Bouc Y. 2003. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 421:182-187.
38. Hsu P. P., Kang S. A., Rameseder J., Zhang Yi., Sabatini D. M. 2011. The mTOR-regulated phosphoproteome reveals a mechanism of mTORCl-mediated inhibition of growth factor signaling. Science. 332:1317-1322.
39. Huang S., Houghton P. J. 2001. Mechanisms of resistance to rapamycins. Drug Resist. Updat. 4:378-391.
40. Huang J., Manning B. D. 2008. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412:179-190.
41. Huang J., Manning B. D. 2009. A complex interplay between Akt, TSC2 and two mTOR complexes. Biochem. Soc. Transactions. 37:217-222.
42. Huang J., Wu S., Wu C.-L., Manning B. D. 2009. Signal events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for tuberous sclerosis complex tumor suppressors. Cancer Res. 69:6107-6114.
43. Hwangbo D. S., Gershman B., Tu M. P., Palmer M., Tatar M. 2004. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature. 429:562-566.
44. Ichetovkin I., Grant W., Condeelis J. 2002. Cofilin produces newly polymerized actin filaments that are preferred for dendritic nucleation by the Arp2/3 complex. Curr. Biol. 12:79-84.
45. Inoki K., Zhu T., Lindvall C., Guan K. L. 2006. TSC2 integrate Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 126:955-968.
46. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M. A., Hall A., Hall M. N. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biol. 6:1122-1128.
47. Jia K., Chen D., Riddle D. L. 2004. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development. 131:3897-3906.
48. Julien L.-A., Carriere A., Moreau J., Roux P. P. 2010. mTORC 1-activated S6K1 phosphorylates rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 30:908-921.
49. Jurivich D. A., Chung J., Blenis J. 1991. Heat shock induces two distinct S6 protein kinase activities in quiescent mammalian fibroblasts. J. Cell. Physiol. 148:252-259.
50. Kapahi P., Zid B. M., Harper T., Koslover D., Sapin V., Benzer S. 2004. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 14:885-890.
51. Kasdan L. A., Lu G., Singha U., Lentzsch S., Roadman G. D., Ghobrial I. M. 2005. Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis in Multiple Myeloma (MM). J. Clinical Oncol. ASCO Annual Meeting Proceedings. 23, Part I of II (Supplement): 9609.
52. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M. D. 2001. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Develop. Biol. 17:615-675.
53. Keniry M., Parsons R. 2008. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 27:5477-5485.
54. Klionsky D. J. 2005. The molecular machinery of autophagy: unanswered questions. J. Cell Sci. 118:7-18.
55. Lang S. A., Moser C., Fichnter-Feigl S., Schachtschneider P., Hellerbrand C., Schmitz V., Schlitt H. J., Geissler E. K., Stoeltzing O. 2009. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology. 49:523-532.
56. Lee S., Helfman D. M. 2004. Cytoplasmic p21 Cipl is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J. Biol. Chem. 279:1885-1891.
57. Levine A. J., Feng Z., Mak T. W., You H., Jin S. 2006. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Develop. 20:267-275.
58. Li W., Petrimpol M., Molle K. D., Hall M. N., Battegay E. J., Humar R. 2007. Hypoxia-induced endothelial proliferation requires both mTORC 1 and mTORC2. Circ. Res. 100:79-87.
59. Lim L., Manser K., Leung T., Hall C. 1996. Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways. Eur. J. Biochem. 242:171-185.
60. Liu L., Chen L., Chung J., Huang S. 2008. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene. 27:4998-5010.
61. Liu L., Luo Y., Chen L., Shen T., Xu B., Chen W., Zhou H., Han X., Huang S. 2010. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J. Biol. Chem. 285:38362-38372.
62. Liu X., Zheng X. F. 2007. Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin. Mol. Biol. Cell. 18:1073-1082.
63. Majewski N., Nogueira V., Bhaskar P., Coy P. E., Hay N. 2004. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell. 16:819-830.
64. E explains its effects on cell proliferation. PLoS ONE. 2:e242.
65. Manning B. D., Logsdon M. N., Lipovsky A. I., Abbott D., Kwiatkowski D. J., Cantley L. C. 2005. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Develop. 19:1773-1778.
66. Martel R. R., Klicius J., Galet S. 1977. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55:48-51.
67. Martin J., Masri J., Bernath A., Nishimura R. N., Gera J. 2008. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem. Biophys. Res. Commun. 372:578-583.
68. Martinez-Outschoorn U. E., Whitaker-Menezes D., Pavlides S., Chiavarina B., Bonuccelli G., Trimmer C., Tsirigos A., Migneco G., Witkiewicz A. K., Balliet R., Mercier I., Wang C., Flomenberg N., Howell A., Lin Z., Caro J., Pestell R. G., Sotgia F., Lisanti M. P. 2010. The autophagic tumor stroma model of cancer or «battery-operated tumor growth». A simple solution to the autophagy paradox. Cell Cycle. 9:4297-4306.
69. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M., Kwiatkowski D. J. 2008. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC 1 and Akt signaling lead to improved survival and function. J. Neurosci. 28:5422-5432.
70. Melendez A., Neufeld T. P. 2008. The cell biology of autophagy in metazoans: a developing story. Development. 135:2347-2360.
71. Narita M., Young A. R., Narita M. 2009. Autophagy facilitates oncogen-induced senescence. Autophagy. 7:1046-1047.
72. Oldham S., Montagne J., Radimerski T., Thomas G., Hafen E. 2000. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Develop. 14:2689-2694.
73. O'Reilly K. E., Rojo K., She Q. B., Solit D., Mills G. B., Smith D., Lane H., Hofmann F., Hicklin D. J., Ludwig D. L., Baselga J., Rosen N. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-1508.
74. QianS. B., Zhang X., Sun J., Bennink J. R., Yewdell J. W., Patterson C. 2010. mTORC 1 links protein quality and quantity control by sensing chaperone availability. J. Biol. Chem. 285:27 385-27 395.
75. Ridley A. J., Allen W. E., Peppelenbosch M., Jones G. E. 1999. Rho family proteins and cell migration. Biochem. Soc. Symp. 65:111-123.
76. Romanov V. S., Bardin A. A., Zubova S. G., Bykova T. V., Pospelov V. A., Pospelova T. V. 2011. p21 Wafl is required for complete oncogenic transformation of mouse embryo fibroblasts by Elad5 and c-Ha-ras oncogenes. Biochimie. 93:1408-1414.
77. Sarbassov D. D., Ali S. M., Sabatini D. M. 2005. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17:596-603.
78. Sarbassov D. D., Ali S. M., Sengupta S., Sheen J. H., Hsu P. P., Bagley A. F., Markhard A. L., Sabatini D. M. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22:159-168.
79. Schieke S. M., Finkel T. 2006. Mitochondrial signaling, TOR and life span. Biol. Chem. 387:1357-1361.
80. Schieke S. M., Phillips D., McCoy J. P., Aponte A. M., Shen R. F., Balaban R. S., Finkel T. 2006. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. Biol. Chem. 281:27643-27652.
81. Scott R. C., Juhasz G., Neufeld T. P. 2007. Direct induction of autophagy by Atgl inhibits cell growth and induces apoptotic cell death. Curr. Biol. 17:1-11.
82. Sehgal S. N. 2003. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 35:7S-14S.
83. Sell C., Lorenzini S. 2007. Aging in IGF-1 hypomorphic mice. Current directions in studying mechanisms of aging. Age. 29:105-106.
84. Selman C., Tullet J. M., Wieser D., Irvine E., Lingard S. J., Choudhury A. I., Claret M., Al-Qassab H., Carmignac D., Ramadani F., Woods A., Robinson I. C., Schuster E., Batterham R. L., Kozma S. C., Thomas G., Carling D., Okkenhaug K., Thornton J. M., Partridge L., Gems D., Withers D. J. 2009. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 326:140-144.
85. Shah O. J., Hunter T. 2006. Turnover of the active fraction of IRS1 involves Raptor-mTOR and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol. Cell. Biol. 26:6425-6434.
86. Shaw R. J., Cantley L. S. 2006. Ras, PI (3) K and mTOR signaling controls tumour cell growth. Nature. 441:424-430.
87. Shi Y., Yan H., Frost P., Gera J., Lichtenstein A. 2005. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4:1533-1540.
88. Sidani M., Wessels D., Mouneimne G., Ghosh M., Goswami S., Sarmiento C., Wang W., Kuhl S., El-Sibai M., Backer J. M., Eddy R., Soil D., Condeelis J. 2007. Cofilin determines the migration behavior and turning frequency of metastatic cancer cells. J. Cell Biol. 179:777-791.
89. Skeen J. E., Bhaskar P. T., Chen C. C., Chen W. S., PengX. D., Nogueira V., Hahn-Windgassen A., Kiyokawa H., Hay N. 2006. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORCl-dependent manner. Cancer Cell. 10:269-280.
90. Steelman L. S., Chappell W. H., Abrams S. L., Kempf R. C., Long J., Laidler P., Mijatovic S., Maksimovic-Ivanic D., Stivala F., Mazzarino M. C., Donia M., Fagone P., Malaponte G., Nicoletti F., Libra M., Milella M., Tafuri A., Bonati A., Basecke J., Cocco L., Evangelisti C., Martelli A. M., Montalto G., Cervello M., McCubrey J. A. 2011. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 3:192-222.
91. Sugrue M. M., Shin D. Y., Lee S. W., Aaronson S. A. 1997. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Nat. Acad. Sci. USA. 94:9648-9653.
92. Tasdemir E., Maiuri M. G., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelia M., Criollo A., Morselli E., Zhu C., Harper F., Nannmark U., Samara C., Pinton P., Vicencio J. M., Carnuccio R., Moll U. M., Madeo F., Paterlini-Brechot P., Rizzuto R., Szabadkai G., Pierron G., Blomgren K., Tavernarakis N., Codogno P., Cecconi F., Kroemer G. 2008. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 10:676-687.
93. Vezina C., Kudelski A., Sehgal S. N. 1975. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo). 28:721-726.
94. Vivanco I., Sawyers C. L. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:489-501.
95. Vries R. G., Flynn A., Patel J. C., Wang X., Denton R. M., Proud C. G. 1997. Heat shock increases the association of binding protein-1 with initiation factor 4E. J. Biol. Chem. 272:32779-32784.
96. Wan X., Helman L. J. 2008. PI3K/Akt/mTOR signaling pathway: implications for human cancer. In: Oncogene proteins: structure, functions and analyses. New York: Nova Sci. Publ., Inc. 87-115.
97. Wang M. C., Bohmann D., Jasper H. 2005. JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell. 121:115-125.
98. Warburg O. 1924. Uber den stoffwechsel der carcinom zelle. Biochem. Z. 152:309-344.
99. Way S. W., McKenna J., 3rd, Mietzsch U., Reith R. M., Wu H. C., Gambello M. J. 2009. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum. Mol. Genet. 18:1252-1265.
100. Weinberg R. A. 1995. The molecular basis of oncogenes and tumor suppressor genes. Ann. N. Y. Acad. Sci. 758:331-338.
101. Yokoo T., Toyoshima H., Miura M., Wang Y., Iida K. T., Suzuki H., Sone H., Shimano H., Gotoda T., Nishimori S., Tanaka K., Yamada N. 2003. p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus. J. Biol. Chem. 278:52919-52923.
102. Yonghao Yu., Yoon S.-O., Poulogiannis G., Yang Q., Blenis J. 2011. Phosphoproteomic analysis identifies GrblO as an mTORCl substrate that negatively regulates insulin signaling. Science. 332:1322-1326.
103. Zeng L. H., Xu L., Gutmann D. H., Wong M. 2008. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 63:444-453.
104. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A. P., Dabora S. L., Griffin J. D., Kwiatkowski D. J. 2007. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 117:730-738.
105. Zhang H., Stallock J. P., Ng J. C., Reinhard C., Neufeld T. P. 2000. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Develop. 14:2712-2724.
106. Zang Y., Zheng S. 2012. mTOR-independent 4E-BPl phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle. 11:594-603.
107. Zhang X., Tang N., Hadden T. J., Rishi A. K. 2011. Akt, FOXO and regulation of apoptosis. Biochim. biophys. acta. 1813:1978-1986.
108. Zhou B. P., Liao Y., Xia W., Zou Y., Spohn B., Hung M. C. 2001. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3:973-982.